Subscribe to Newsletter
Business & Regulation Business Practice, Contract Development Services, Contract Manufacturing Services, Facilities, Quality & Compliance, Small Molecules, Standards & Regulation

GDUFA 2020

Generic Drug User Fee rates for fiscal year 2020 (beginning October 1, 2019) have been published by the FDA (1). The fees specify what companies must pay for Abbreviated New Drug Applications (ANDA), Drug Master File (DFM) submissions, annual active ANDA holdings, and API and finished dosage form facilities. Compared with the previous year, the fees for Finished Dosage Form (FDF) facilities have dropped by around 6 to 7.4 percent.

GDUFA fees help fund the FDA review process, including research activities for investigating new methodologies and tools for the development of generic drugs. In fiscal year 2018, the FDA’s Office of Generic Drugs awarded 13 new research contracts and 11 grants for research projects on generics, including complex active ingredients, formulations and dosage forms; complex routes of delivery; complex drug-device combination projects; and tools and methodologies for bioequivalence and substitutability evaluation. GDUFA has also helped fund the development of 136 new product specific guidelines as a roadmap for generic drug development (2).

When the user fees were first introduced, they were structured in a way that unintentionally created a large fee burden on contract manufacturers. Since then, the Pharma & Biopharma Outsourcing Association (PBOA) has been advocating to ensure the GDUFA program – and other FDA programs – are fair to the contract manufacturing sector. You can read more about PBOA and its effect on GDUFA fees in a previous cover feature of The Medicine Maker, “Standing Up for the Invisible Manufacturers,” featuring Gil Roth, President at PBOA.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Department of Health and Human Services, “Generic Drug User Fee Rates for Fiscal Year 2020,” (2019). Available at Last accessed July 29, 2019. 
  2. FDA, “Office of Generic Drugs FY 2018 GDUFA Science and Research Report,” (2019). Available at Last accessed July 29, 2019. 
About the Author
Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Related White Papers
Nitrosamines Risk Mitigation: The critical role of excipients and supplier qualification

| Contributed by DFE Pharma GmbH & Co. KG

Performance validation of ScatterX78 against NIST reference materials

| Contributed by Malvern Panalytical

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine